Calabrese Carlo, Fabbri Anna, Di Febo Giulio
Department of Internal Medicine and Gastroenterology, University of Bologna, Italy.
Clin Interv Aging. 2007;2(1):85-92. doi: 10.2147/ciia.2007.2.1.85.
The prevalence of gastroesophageal reflux disease (GERD) increases with age and elderly are more likely to develop severe disease. Older patients often complain of less severe or frequent heartburn than younger patients and they may present with atypical symptoms such as dysphagia, weight loss, or extraesophageal symptoms. Proton pump inhibitors (PPIs) are central in the management of GERD and are unchallenged with regards to their efficacy. They are considered safe and more effective than histamine receptor antagonists for healing esophagitis and for preventing its recurrence using a long term maintenance treatment. PPI have minimal side effects and few slight drug interactions and are considered safe for long term treatment. Pantoprazole is significantly effective both for acute and long-term treatment with excellent control of relapse and symptoms. It is well tolerated even for long-term therapy and its tolerability is optimal. Pantoprazole shows to have minimal interactions with other drugs because of a lower affinity for cytocrome P450 than older PPIs. Although the majority of elderly has concomitant illnesses and receive other drugs, this does not adversely effect the efficacy of pantoprazole because of its pharmacokinetics, which are independent of patient age. Clinical practice suggests that a low dose maintenance of PPIs should be used in older patients with GERD.
胃食管反流病(GERD)的患病率随年龄增长而增加,老年人更易患严重疾病。老年患者常抱怨烧心症状不如年轻患者严重或频繁,他们可能表现出吞咽困难、体重减轻或食管外症状等非典型症状。质子泵抑制剂(PPI)是GERD治疗的核心药物,其疗效无可争议。在治疗食管炎及通过长期维持治疗预防其复发方面,PPI被认为比组胺受体拮抗剂更安全、更有效。PPI副作用极小,药物相互作用轻微,被认为长期治疗安全。泮托拉唑在急性和长期治疗中均显著有效,能很好地控制复发和症状。即使长期治疗,其耐受性也良好,耐受性最佳。由于泮托拉唑对细胞色素P450的亲和力低于其他老一代PPI,与其他药物的相互作用极小。尽管大多数老年人患有合并症并服用其他药物,但由于其药代动力学不受患者年龄影响,这不会对泮托拉唑的疗效产生不利影响。临床实践表明,老年GERD患者应采用低剂量PPI维持治疗。